drugset
drugset / Trial / NCT07464756

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

NCT07464756 ↗

Phase 2 Recruiting 80 enrolled The First Affiliated Hospital with Nanjing Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a multicenter, randomized, two-cohort clinical trial to evaluate the efficacy and safety of SHR-1701 with or without apatinib in combined with chemotherapy of neoadjuvant treatment for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.

Timeline

Start
2026-04-03
Primary completion
2028-05-31
Completion
2030-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Retlirafusp alfa Protein / enzyme biologic 1800 mg —
Subject Rivoceranib Small molecule 250 mg —
Background Oxaliplatin Small molecule — —
Background S-1 Small molecule — —

Indications

gastric adenocarcinoma